Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nova Eye MedicalELXMF -0.03%48 Debt-to-Equity is 0.18 as of Dec. 2025, which is 13% above its 10-year median of 0.16. GuruFocus rates ELXMF with a GF Score™ of 48/100 and a GF Value™ of $0.02. The stock has 4 warning signs investors should review. Among 706 Medical Devices & Instruments companies, Nova Eye Medical ranks better than 55.24% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Nova Eye Medical's Debt-to-Equity or its related term are showing as below:
ELXMF'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.03 Med: 0.16 Max: 0.28
Current: 0.18
During the past 13 years, the highest Debt-to-Equity Ratio of Nova Eye Medical was 0.28. The lowest was 0.03. And the median was 0.16.
ELXMF's Debt-to-Equity is ranked better than 55.24% of 706
companies
in the Medical Devices & Instruments industry
Industry Median: 0.23
vs ELXMF: 0.18
Nova Eye Medical (OTCPK:ELXMF) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Nova Eye Medical Debt-to-Equity Related Terms
Nova Eye Medical Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Nova Eye Medical's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Nova Eye Medical's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical Debt-to-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (ELXMF) has a Debt-to-Equity of 0.18 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nova Eye Medical and its competitors. This is 13% above median its historical median of 0.16. Over the past decade, Nova Eye Medical's Debt-to-Equity has ranged from 0.03 to 0.28. According to the industry distribution chart, Nova Eye Medical ranks #316 out of 706 companies in the Medical Devices & Instruments industry, placing it in the top 44.8%.
Is Nova Eye Medical's Debt-to-Equity too high?
Nova Eye Medical's current Debt-to-Equity of 0.18 is 13% above median its 10-year median of 0.16. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 0.28. The Medical Devices & Instruments industry median Debt-to-Equity is 0.23. Nova Eye Medical's value of 0.18 is 21.7% below this industry median. Based on the distribution chart, Nova Eye Medical ranks #316 out of 706 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Nova Eye Medical has a GF Score™ of 48/100, reflecting its overall financial health beyond just this single metric.
How does Nova Eye Medical's Debt-to-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Nova Eye Medical ranks #316 out of 706 companies for Debt-to-Equity. This puts Nova Eye Medical in the upper half of its industry. The industry median Debt-to-Equity is 0.23. Nova Eye Medical's value of 0.18 is 21.7% below this benchmark. Historically, Nova Eye Medical's own Debt-to-Equity has ranged from 0.03 to 0.28 over the past decade. While the company's 10-year median is 0.16 vs. the industry median of 0.23, Nova Eye Medical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Devices & Instruments company?
The median Debt-to-Equity among Medical Devices & Instruments companies is 0.23, based on 706 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Nova Eye Medical's current Debt-to-Equity of 0.18 is 21.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Nova Eye Medical and its competitors. For the Medical Devices & Instruments industry, the median Debt-to-Equity is 0.23 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Nova Eye Medical's current Debt-to-Equity is 0.18, which is 13% above median its own 10-year median of 0.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nova Eye Medical stock overvalued right now?
Nova Eye Medical (ELXMF) has a current Debt-to-Equity of 0.18. The stock's GF Value™ is $0.02, compared to a current price of $0.01 — trading 28.5% below its estimated fair value. The current Debt-to-Equity is 0.18, which is 13% above median its 10-year median of 0.16 and 21.7% below the Medical Devices & Instruments industry median of 0.23. Nova Eye Medical's overall GF Score™ is 48/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Nova Eye Medical (ELXMF), the current Debt-to-Equity is 0.18 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nova Eye Medical (ELXMF) Overvalued in 2026?
Based on GuruFocus' analysis, Nova Eye Medical stock appears to be undervalued.
The current stock price of $0.01 is trading 28.5% below its estimated GF Value™ of $0.02.
Key valuation signals for ELXMF:
Debt-to-Equity: 0.18 (13% above median its 10-year median of 0.16)
GF Value™: $0.02 vs. price of $0.01 (28.5% below fair value)
Industry Position: 21.7% below the Medical Devices & Instruments median (#316 of 706)
No single metric tells the full story. See the ELXMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nova Eye Medical Ltd develops and sells surgical devices for the treatment of glaucoma, a cause of blindness. In addition, the company is involved in the commercialisation of the subthreshold nano-pulse ophthalmic laser, 2RT, for the treatment of retinal disease via the AlphaRET segment. The company's reportable segments are: Glaucoma Surgical Devices and AlphaRET. The majority of its revenue is generated from the Glaucoma Surgical Devices segment, which is involved in the design, manufacture, marketing, and sale of the iTrack, iTrack Advance, and the Molteno3 glaucoma surgical device. These are all single-use surgical devices. Geographically, the company generates maximum revenue from the United States of America, followed by Europe, the Asia Pacific, Other regions, and Australia.
48GF Score
Get the complete analysis for ELXMF
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELXMF has been successfully added to your 
